An  ||| S:0 E:3 ||| DT
analysis  ||| S:3 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
the  ||| S:15 E:19 ||| DT
long-term  ||| S:19 E:29 ||| JJ
safety  ||| S:29 E:36 ||| NN
data  ||| S:36 E:41 ||| NNS
of  ||| S:41 E:44 ||| IN
repeat  ||| S:44 E:51 ||| NN
administrations  ||| S:51 E:67 ||| NNS
of  ||| S:67 E:70 ||| IN
botulinum  ||| S:70 E:80 ||| JJ
neurotoxin  ||| S:80 E:91 ||| JJ
type  ||| S:91 E:96 ||| NN
A-ABO  ||| S:96 E:102 ||| NN
for  ||| S:102 E:106 ||| IN
the  ||| S:106 E:110 ||| DT
treatment  ||| S:110 E:120 ||| NN
of  ||| S:120 E:123 ||| IN
glabellar  ||| S:123 E:133 ||| JJ
lines  ||| S:133 E:139 ||| NNS
A  ||| S:139 E:141 ||| DT
new  ||| S:141 E:145 ||| JJ
formulation  ||| S:145 E:157 ||| NN
of  ||| S:157 E:160 ||| IN
botulinum  ||| S:160 E:170 ||| JJ
neurotoxin  ||| S:170 E:181 ||| JJ
type  ||| S:181 E:186 ||| NN
A  ||| S:186 E:188 ||| DT
( ||| S:188 E:189 ||| -LRB-
BoNTA-ABO ||| S:189 E:198 ||| NNP
;  ||| S:198 E:200 ||| :
Dysport  ||| S:200 E:208 ||| NNP
[ ||| S:208 E:209 ||| -LRB-
abobotulinumtoxinA ||| S:209 E:227 ||| NNP
] ||| S:227 E:228 ||| -RRB-
;  ||| S:228 E:230 ||| :
Medicis  ||| S:230 E:238 ||| NNP
Aesthetics ||| S:238 E:248 ||| NNP
,  ||| S:248 E:250 ||| ,
Scottsdale ||| S:250 E:260 ||| NNP
,  ||| S:260 E:262 ||| ,
AZ ||| S:262 E:264 ||| NNP
)  ||| S:264 E:266 ||| -RRB-
was  ||| S:266 E:270 ||| VBD
recently  ||| S:270 E:279 ||| RB
approved  ||| S:279 E:288 ||| VBN
by  ||| S:288 E:291 ||| IN
the  ||| S:291 E:295 ||| DT
US  ||| S:295 E:298 ||| NNP
Food  ||| S:298 E:303 ||| NNP
and  ||| S:303 E:307 ||| CC
Drug  ||| S:307 E:312 ||| NNP
Administration  ||| S:312 E:327 ||| NNP
for  ||| S:327 E:331 ||| IN
the  ||| S:331 E:335 ||| DT
treatment  ||| S:335 E:345 ||| NN
of  ||| S:345 E:348 ||| IN
moderate  ||| S:348 E:357 ||| JJ
to  ||| S:357 E:360 ||| TO
severe  ||| S:360 E:367 ||| JJ
glabellar  ||| S:367 E:377 ||| JJ
lines ||| S:377 E:382 ||| NNS
.  ||| S:382 E:384 ||| .
To  ||| S:384 E:387 ||| TO
assess  ||| S:387 E:394 ||| VB
the  ||| S:394 E:398 ||| DT
long-term  ||| S:398 E:408 ||| JJ
safety  ||| S:408 E:415 ||| NN
of  ||| S:415 E:418 ||| IN
repeat  ||| S:418 E:425 ||| NN
administrations  ||| S:425 E:441 ||| NNS
of  ||| S:441 E:444 ||| IN
BoNTA-ABO  ||| S:444 E:454 ||| JJ
for  ||| S:454 E:458 ||| IN
the  ||| S:458 E:462 ||| DT
treatment  ||| S:462 E:472 ||| NN
of  ||| S:472 E:475 ||| IN
glabellar  ||| S:475 E:485 ||| JJ
lines ||| S:485 E:490 ||| NNS
,  ||| S:490 E:492 ||| ,
including  ||| S:492 E:502 ||| VBG
variable  ||| S:502 E:511 ||| JJ
dosing ||| S:511 E:517 ||| NN
.  ||| S:517 E:519 ||| .
This  ||| S:519 E:524 ||| DT
report  ||| S:524 E:531 ||| NN
summarizes  ||| S:531 E:542 ||| VBD
an  ||| S:542 E:545 ||| DT
interim  ||| S:545 E:553 ||| JJ
analysis  ||| S:553 E:562 ||| NN
that  ||| S:562 E:567 ||| WDT
does  ||| S:567 E:572 ||| VBZ
not  ||| S:572 E:576 ||| RB
address  ||| S:576 E:584 ||| VB
the  ||| S:584 E:588 ||| DT
efficacy  ||| S:588 E:597 ||| JJ
profile ||| S:597 E:604 ||| NN
.  ||| S:604 E:606 ||| .
Over  ||| S:606 E:611 ||| IN
24  ||| S:611 E:614 ||| CD
months ||| S:614 E:620 ||| NNS
,  ||| S:620 E:622 ||| ,
1415  ||| S:622 E:627 ||| CD
subjects  ||| S:627 E:636 ||| NNS
underwent  ||| S:636 E:646 ||| VBD
open-label  ||| S:646 E:657 ||| JJ
retreatment  ||| S:657 E:669 ||| NN
with  ||| S:669 E:674 ||| IN
BoNTA-ABO ||| S:674 E:683 ||| JJ
.  ||| S:683 E:685 ||| .
Patients  ||| S:685 E:694 ||| NNS
were  ||| S:694 E:699 ||| VBD
retreated  ||| S:699 E:709 ||| VBN
with  ||| S:709 E:714 ||| IN
50  ||| S:714 E:717 ||| CD
units  ||| S:717 E:723 ||| NNS
or  ||| S:723 E:726 ||| CC
a  ||| S:726 E:728 ||| DT
variable  ||| S:728 E:737 ||| JJ
dose  ||| S:737 E:742 ||| NN
of  ||| S:742 E:745 ||| IN
50 ||| S:745 E:747 ||| CD
,  ||| S:747 E:749 ||| ,
60 ||| S:749 E:751 ||| CD
,  ||| S:751 E:753 ||| ,
70 ||| S:753 E:755 ||| CD
,  ||| S:755 E:757 ||| ,
or  ||| S:757 E:760 ||| CC
80  ||| S:760 E:763 ||| CD
units  ||| S:763 E:769 ||| NNS
based  ||| S:769 E:775 ||| VBN
on  ||| S:775 E:778 ||| IN
gender  ||| S:778 E:785 ||| NN
and  ||| S:785 E:789 ||| CC
muscle  ||| S:789 E:796 ||| NN
mass ||| S:796 E:800 ||| NN
.  ||| S:800 E:802 ||| .
Dose  ||| S:802 E:807 ||| NNP
was  ||| S:807 E:811 ||| VBD
divided  ||| S:811 E:819 ||| VBN
among  ||| S:819 E:825 ||| IN
five  ||| S:825 E:830 ||| CD
points  ||| S:830 E:837 ||| NNS
in  ||| S:837 E:840 ||| IN
the  ||| S:840 E:844 ||| DT
glabellar  ||| S:844 E:854 ||| JJ
region ||| S:854 E:860 ||| NN
.  ||| S:860 E:862 ||| .
Retreatments  ||| S:862 E:875 ||| NNP
were  ||| S:875 E:880 ||| VBD
performed  ||| S:880 E:890 ||| VBN
if  ||| S:890 E:893 ||| IN
at  ||| S:893 E:896 ||| IN
least  ||| S:896 E:902 ||| JJS
85  ||| S:902 E:905 ||| CD
days  ||| S:905 E:910 ||| NNS
had  ||| S:910 E:914 ||| VBD
elapsed  ||| S:914 E:922 ||| VBN
between  ||| S:922 E:930 ||| IN
treatments  ||| S:930 E:941 ||| NNS
and  ||| S:941 E:945 ||| CC
the  ||| S:945 E:949 ||| DT
glabellar  ||| S:949 E:959 ||| JJ
line  ||| S:959 E:964 ||| NN
severity  ||| S:964 E:973 ||| NN
score  ||| S:973 E:979 ||| NN
was  ||| S:979 E:983 ||| VBD
reassessed  ||| S:983 E:994 ||| VBN
as  ||| S:994 E:997 ||| IN
moderate  ||| S:997 E:1006 ||| JJ
or  ||| S:1006 E:1009 ||| CC
severe ||| S:1009 E:1015 ||| JJ
.  ||| S:1015 E:1017 ||| .
Patients  ||| S:1017 E:1026 ||| NNS
were  ||| S:1026 E:1031 ||| VBD
followed  ||| S:1031 E:1040 ||| VBN
up  ||| S:1040 E:1043 ||| RP
at  ||| S:1043 E:1046 ||| IN
seven ||| S:1046 E:1051 ||| CD
,  ||| S:1051 E:1053 ||| ,
14 ||| S:1053 E:1055 ||| CD
,  ||| S:1055 E:1057 ||| ,
and  ||| S:1057 E:1061 ||| CC
30  ||| S:1061 E:1064 ||| CD
days  ||| S:1064 E:1069 ||| NNS
postinjection ||| S:1069 E:1082 ||| NN
,  ||| S:1082 E:1084 ||| ,
then  ||| S:1084 E:1089 ||| RB
monthly ||| S:1089 E:1096 ||| JJ
.  ||| S:1096 E:1098 ||| .
Endpoints  ||| S:1098 E:1108 ||| NNP
were  ||| S:1108 E:1113 ||| VBD
adverse  ||| S:1113 E:1121 ||| JJ
events  ||| S:1121 E:1128 ||| NNS
( ||| S:1128 E:1129 ||| -LRB-
AE ||| S:1129 E:1131 ||| NNP
) ||| S:1131 E:1132 ||| -RRB-
.  ||| S:1132 E:1134 ||| .
Of  ||| S:1134 E:1137 ||| IN
1415  ||| S:1137 E:1142 ||| CD
patients ||| S:1142 E:1150 ||| NNS
,  ||| S:1150 E:1152 ||| ,
932  ||| S:1152 E:1156 ||| CD
( ||| S:1156 E:1157 ||| -LRB-
66 ||| S:1157 E:1159 ||| CD
% ||| S:1159 E:1160 ||| NN
)  ||| S:1160 E:1162 ||| -RRB-
experienced  ||| S:1162 E:1174 ||| VBN
at  ||| S:1174 E:1177 ||| IN
least  ||| S:1177 E:1183 ||| JJS
one  ||| S:1183 E:1187 ||| CD
AE ||| S:1187 E:1189 ||| NNS
.  ||| S:1189 E:1191 ||| .
The  ||| S:1191 E:1195 ||| DT
rate  ||| S:1195 E:1200 ||| NN
of  ||| S:1200 E:1203 ||| IN
treatment-emergent  ||| S:1203 E:1222 ||| NNP
AE  ||| S:1222 E:1225 ||| NNP
( ||| S:1225 E:1226 ||| -LRB-
TEAE ||| S:1226 E:1230 ||| NNP
)  ||| S:1230 E:1232 ||| -RRB-
was  ||| S:1232 E:1236 ||| VBD
similar  ||| S:1236 E:1244 ||| JJ
in  ||| S:1244 E:1247 ||| IN
both  ||| S:1247 E:1252 ||| PDT
the  ||| S:1252 E:1256 ||| DT
fixed-  ||| S:1256 E:1263 ||| JJ
and  ||| S:1263 E:1267 ||| CC
variable-dose  ||| S:1267 E:1281 ||| JJ
groups ||| S:1281 E:1287 ||| NNS
.  ||| S:1287 E:1289 ||| .
Most  ||| S:1289 E:1294 ||| JJS
TEAE  ||| S:1294 E:1299 ||| NNP
were  ||| S:1299 E:1304 ||| VBD
rated  ||| S:1304 E:1310 ||| VBN
mild  ||| S:1310 E:1315 ||| JJ
( ||| S:1315 E:1316 ||| -LRB-
70 ||| S:1316 E:1318 ||| CD
% ||| S:1318 E:1319 ||| NN
)  ||| S:1319 E:1321 ||| -RRB-
or  ||| S:1321 E:1324 ||| CC
moderate  ||| S:1324 E:1333 ||| JJ
( ||| S:1333 E:1334 ||| -LRB-
20 ||| S:1334 E:1336 ||| CD
% ||| S:1336 E:1337 ||| NN
) ||| S:1337 E:1338 ||| -RRB-
.  ||| S:1338 E:1340 ||| .
The  ||| S:1340 E:1344 ||| DT
majority  ||| S:1344 E:1353 ||| NN
( ||| S:1353 E:1354 ||| -LRB-
87 ||| S:1354 E:1356 ||| CD
% ||| S:1356 E:1357 ||| NN
;  ||| S:1357 E:1359 ||| :
3361 ||| S:1359 E:1363 ||| CD
/ ||| S:1363 E:1364 ||| CD
3861 ||| S:1364 E:1368 ||| CD
)  ||| S:1368 E:1370 ||| -RRB-
of  ||| S:1370 E:1373 ||| IN
all  ||| S:1373 E:1377 ||| DT
TEAE  ||| S:1377 E:1382 ||| NNP
instances  ||| S:1382 E:1392 ||| NNS
were  ||| S:1392 E:1397 ||| VBD
considered  ||| S:1397 E:1408 ||| VBN
not  ||| S:1408 E:1412 ||| RB
related  ||| S:1412 E:1420 ||| VBN
or  ||| S:1420 E:1423 ||| CC
unlikely  ||| S:1423 E:1432 ||| JJ
to  ||| S:1432 E:1435 ||| TO
be  ||| S:1435 E:1438 ||| VB
related  ||| S:1438 E:1446 ||| VBN
to  ||| S:1446 E:1449 ||| TO
study  ||| S:1449 E:1455 ||| VB
treatment ||| S:1455 E:1464 ||| NN
.  ||| S:1464 E:1466 ||| .
The  ||| S:1466 E:1470 ||| DT
overall  ||| S:1470 E:1478 ||| JJ
incidence  ||| S:1478 E:1488 ||| NN
of  ||| S:1488 E:1491 ||| IN
TEAE  ||| S:1491 E:1496 ||| NNP
and  ||| S:1496 E:1500 ||| CC
related  ||| S:1500 E:1508 ||| JJ
events  ||| S:1508 E:1515 ||| NNS
remained  ||| S:1515 E:1524 ||| VBD
relatively  ||| S:1524 E:1535 ||| RB
constant  ||| S:1535 E:1544 ||| JJ
or  ||| S:1544 E:1547 ||| CC
decreased  ||| S:1547 E:1557 ||| VBD
over  ||| S:1557 E:1562 ||| IN
repeat  ||| S:1562 E:1569 ||| NN
cycles ||| S:1569 E:1575 ||| NNS
.  ||| S:1575 E:1577 ||| .
Multiple  ||| S:1577 E:1586 ||| JJ
cycles  ||| S:1586 E:1593 ||| NNS
with  ||| S:1593 E:1598 ||| IN
fixed  ||| S:1598 E:1604 ||| JJ
or  ||| S:1604 E:1607 ||| CC
variable  ||| S:1607 E:1616 ||| JJ
dosing  ||| S:1616 E:1623 ||| NN
of  ||| S:1623 E:1626 ||| IN
BoNTA-ABO  ||| S:1626 E:1636 ||| NNS
are  ||| S:1636 E:1640 ||| VBP
well  ||| S:1640 E:1645 ||| RB
tolerated ||| S:1645 E:1654 ||| VBN
.  ||| S:1654 E:1656 ||| .
There  ||| S:1656 E:1662 ||| EX
was  ||| S:1662 E:1666 ||| VBD
no  ||| S:1666 E:1669 ||| DT
evidence  ||| S:1669 E:1678 ||| NN
of  ||| S:1678 E:1681 ||| IN
cumulative  ||| S:1681 E:1692 ||| JJ
safety  ||| S:1692 E:1699 ||| NN
issues  ||| S:1699 E:1706 ||| NNS
because  ||| S:1706 E:1714 ||| IN
the  ||| S:1714 E:1718 ||| DT
incidence  ||| S:1718 E:1728 ||| NN
of  ||| S:1728 E:1731 ||| IN
AE  ||| S:1731 E:1734 ||| NNP
remained  ||| S:1734 E:1743 ||| VBD
relatively  ||| S:1743 E:1754 ||| RB
constant  ||| S:1754 E:1763 ||| JJ
or  ||| S:1763 E:1766 ||| CC
decreased  ||| S:1766 E:1776 ||| VBD
over  ||| S:1776 E:1781 ||| IN
repeated  ||| S:1781 E:1790 ||| JJ
treatment  ||| S:1790 E:1800 ||| NN
cycles ||| S:1800 E:1806 ||| NNS
.  ||| S:1806 E:1808 ||| .
